INTRODUCING WILDTYPE TP53 IN TP53 MUTATED MYELOID LEUKEMIAS IMPROVES SENSITIVITY TO CHEMOTHERAPEUTIC DRUGS

被引：0
|
作者：
Maity, Arnab [1 ,2 ]
Illangeswaran, Raveen [3 ]
Rajamani, Bharathi [3 ]
Choudhury, Anurag [3 ]
Velayudhan, Shaji [4 ]
Kulkarni, Uday
Balasubramanian, Poonkuzhaki [3 ]
机构：
[1] Christian Med Coll Vellore, Kilminnal Village, India
[2] Reg Ctr Biotechnol Faridabad, Kilminnal Village, India
[3] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
[4] Christian Med Coll & Hosp, Ctr Stem Cell Res, Vellore, Tamil Nadu, India
来源：
EXPERIMENTAL HEMATOLOGY | 2024年 / 137卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3123
引用
收藏
页数：1
相关论文
共 50 条
  • [41] TP53: an oncogene in disguise
    T Soussi
    K G Wiman
    Cell Death & Differentiation, 2015, 22 : 1239 - 1249
  • [42] TP53 and liver carcinogenesis
    Staib, F
    Hussain, SP
    Hofseth, LJ
    Wang, XW
    Harris, CC
    HUMAN MUTATION, 2003, 21 (03) : 201 - 216
  • [43] TP53 and therapy-related myeloid neoplasms
    Chung, Jae
    Sallman, David A.
    Padron, Eric
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (01) : 98 - 103
  • [44] Mutated and non-mutated TP53 as targets in the treatment of leukaemia
    Nahi, H.
    Selivanova, G.
    Lehmann, S.
    Mollgard, L.
    Bengtzen, S.
    Concha, H.
    Svensson, A.
    Wiman, K. G.
    Merup, M.
    Paul, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (04) : 445 - 453
  • [45] Patterns of structural variants within TP53 introns and relocation of the TP53 promoter: a commentary
    Beird, Hannah C.
    Lin, Dimitri
    Lazar, Alexander J.
    Futreal, P. Andrew
    JOURNAL OF PATHOLOGY, 2024, 263 (02): : 131 - 134
  • [46] Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
    A Langerød
    TI Andersen
    I Bukholm
    A-L Børresen Dale
    Breast Cancer Research, 2 (Suppl 1)
  • [47] Clonal expansion of TP53 mutated cells is associated with chemoresistance in acute myeloid leukemia
    Yan, Bowen
    Qiu, Yi
    CANCER RESEARCH, 2019, 79 (13)
  • [48] THERAPEUTIC USE OF IBRUTINIB IN PATIENTS WITH MUTATED LLC TP53
    Adrian, Segura D.
    Natalia, Espinosa L.
    Laura, Lacalle A.
    Marta, Villalba M.
    Gonzalo, Ferrer G.
    Gonzalo, Caballero N.
    Ana Cristina, Godoy M.
    Araceli, Rubio M.
    Pilar, Delgado B.
    HAEMATOLOGICA, 2016, 101 : 335 - 335
  • [49] Current State and Future Prospects of Diagnosis and Management of TP53 Mutated Myeloid Neoplasms
    Venugopal, Sangeetha
    Loghavi, Sanam
    PATHOBIOLOGY, 2024, 91 (01) : 45 - 54
  • [50] What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?
    Wang, Chen
    Sallman, David A.
    CANCER JOURNAL, 2022, 28 (01): : 51 - 61
12345